<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-2391</journal-id>
<journal-title><![CDATA[Acta pediátrica de México]]></journal-title>
<abbrev-journal-title><![CDATA[Acta pediatr. Méx]]></abbrev-journal-title>
<issn>0186-2391</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Pediatría]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-23912017000100026</article-id>
<article-id pub-id-type="doi">10.18233/apm1no1pp26-321321</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento con estatinas en pacientes pediátricos con síndrome nefrótico resistente a esteroides. Reporte de dos casos]]></article-title>
<article-title xml:lang="en"><![CDATA[Statins treatment in pediatric patients with steroid resistant nephrotic syndrome. A two case reports.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-García]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bailón-Ortega]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zaltzman-Girshevich]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Pediatría Departamento de Nefrología Pediátrica ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital de la Niñez Oaxaqueña Nefrología Pediátrica ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Pediatría  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2017</year>
</pub-date>
<volume>38</volume>
<numero>1</numero>
<fpage>26</fpage>
<lpage>32</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-23912017000100026&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-23912017000100026&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-23912017000100026&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El síndrome nefrótico se define por la asociación de proteinuria, hipoalbuminemia, hiperlipidemia y edema. El 80% de los pacientes pediátricos con síndrome nefrótico primario responde a la terapia con esteroides; el 20% restante requiere asociar otros medicamentos para alcanzar la remisión (ciclofosfamida, ciclosporina). La hiperlipidemia en el síndrome nefrótico es debida tanto a un incremento en la síntesis acompañada de disminución en la eliminación de los lípidos de la sangre; siendo la causa directa de esto la proteinuria. La hiperlipidemia incrementa el riesgo cardiovascular, así como el daño glomerular. Con base en esto, la hiperlipidemia persistente en el síndrome nefrótico resistente a esteroides debe ser tratada. Los inhibidores de la 3-hidroxi-3-metilglutaril-coenzima A (HMG-CoA) reductasa han demostrado efecto antiinflamatorio, inmunomodulador y antiproliferativo. Por ello el papel de las estatinas en el síndrome nefrótico va más allá de su efecto hipolipemiante. Presentamos dos casos de pacientes pediátricos con diagnóstico de síndrome nefrótico resistente a esteroides y su evolución durante el tratamiento con ciclosporina y estatinas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The nephrotic syndrome is defined by the association of proteinuria, hypoalbuminemia, hyperlipidemia and edema. 80% of the pediatric patients with primary nephrotic syndrome respond to steroid therapy; the remaining 20% require associate other drugs to achieve remission (cyclophosphamide, cyclosporine). The hyperlipidemia in the nephrotic syndrome is due both to an increased synthesis and decreased elimination of blood lipids; being the direct cause of this the proteinuria. The hyperlipidemia increases cardiovascular risk and glomerular damage. Based on this, the persistent hyperlipidemia in the steroid-resistant nephrotic syndrome should be treated. The HMG-CoA reductase inhibitors have shown immunomodulatory, anti-inflammatory and anti-proliferative effect. Therefore, the role of statins in the nephrotic syndrome goes beyond their lipid-lowering effect. We present two cases of pediatric patients diagnosed with steroid-resistant nephrotic syndrome and its evolution during treatment with cyclosporine and statins.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[proteinuria]]></kwd>
<kwd lng="es"><![CDATA[estatinas]]></kwd>
<kwd lng="es"><![CDATA[síndrome nefrótico]]></kwd>
<kwd lng="es"><![CDATA[hiperlipidemia]]></kwd>
<kwd lng="en"><![CDATA[proteinuria]]></kwd>
<kwd lng="en"><![CDATA[statins]]></kwd>
<kwd lng="en"><![CDATA[nephrotic syndrome]]></kwd>
<kwd lng="en"><![CDATA[hyperlipidemia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Avner]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Harmon]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Niaudet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshikawa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatric nephrology]]></source>
<year>2009</year>
<edition>6th ed</edition>
<page-range>667p</page-range><publisher-loc><![CDATA[Berlin ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Steroid-resistant nephrotic syndrome: long-term evolution after sequential therapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Melgosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Meseguer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Espinoza]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Nephrol]]></source>
<year>2007</year>
<volume>22</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1875-80</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loeffler]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gowrishankar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yiu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Nephrol]]></source>
<year>2004</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>281-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Niaudet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[French Society of Pediatric Nephrology. J Pediatr]]></source>
<year>1994</year>
<volume>125</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>981-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Interventions for idiopathic steroid-resistant nephrotic syndrome in children]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hodson]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Willis]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Craig]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2010</year>
<volume>10</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>CD003594</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Reduction in proteinuria attenuates hyperlipidemia n the nephrotic syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaysen]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Soc Nephrol]]></source>
<year>1990</year>
<volume>1</volume>
<numero>5^sSuppl 2</numero>
<issue>5^sSuppl 2</issue>
<supplement>Suppl 2</supplement>
<page-range>S75-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaysen]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Gambertoglio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Felts]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hutchison]]></surname>
<given-names><![CDATA[FN]]></given-names>
</name>
</person-group>
<source><![CDATA[Kidney Int]]></source>
<year>1987</year>
<volume>31</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1368-76</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Hyperlipidemia in childhood nephrotic syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thabet]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Salcedo]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Nephrol]]></source>
<year>1993</year>
<volume>7</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>559-66</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Should hyperlipidemia in children with the nephrotic syndrome be treated?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Querfeld]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Nephrol]]></source>
<year>1999</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77-84</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duplaga]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Pharmacother]]></source>
<year>1999</year>
<volume>33</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1224-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-de-la-Puente]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arredondo-García]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez-Castrellón]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bojorquez-Ochoa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maya]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Martínez Mdel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Nephrol]]></source>
<year>2009</year>
<volume>24</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1205-10</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Statins in nephrotic syndrome: a new weapon against tissue injury]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buemi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nostro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Crasci]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Barillà]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Consentino]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Aloisi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Res Rev]]></source>
<year>2005</year>
<volume>25</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>587-609</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The Discovery and development of HMC-CoA reductase inhibitors]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Endo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[J Lipid Res]]></source>
<year>1992</year>
<volume>33</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1569-82</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Lipid-lowering therapy in patients with renal disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Massy]]></surname>
<given-names><![CDATA[ZA]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[JZ]]></given-names>
</name>
<name>
<surname><![CDATA[Louis]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Kasiske]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<source><![CDATA[Kidney Int]]></source>
<year>1995</year>
<volume>48</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>188-98</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanjad]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[al-Abbad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[al-Shorafa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pediatr]]></source>
<year>1997</year>
<volume>130</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>470-4</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coleman]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Watson]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Nephrol]]></source>
<year>1996</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>171-4</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prata]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Noqueira]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Correira]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Vicente]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Nephrol]]></source>
<year>1994</year>
<volume>41</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>277-83</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponticelli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Edefonti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Altieri]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rivolta]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rinaldi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Kidney Int]]></source>
<year>1993</year>
<volume>43</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1377-84</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cattran]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Appel]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Hebert]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Hunsicker]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Pohl]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Hoy]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
</person-group>
<source><![CDATA[Kidney Int]]></source>
<year>1999</year>
<volume>56</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2220-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaziri]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Azad]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>2000</year>
<volume>294</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>778-83</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Implication of cholesterol in cyclosporine pharmacodynamics in minimal change nephrotic syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hirano]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kawamura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fukuda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kohsaka]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshikawa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2003</year>
<volume>74</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>581-90</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Amelioration of steroids and cyclosporine-resistant nephrotic syndrome by pravastatin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Machida]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Inaba]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Harada]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Okuyama]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Pediatr Nephrol]]></source>
<year>2007</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>603-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Lipid-lowering agents for nephrotic syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kong]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2013</year>
<volume>10</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>CD005425</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
